PT  - JOURNAL ARTICLE
AU  - Rapier-Sharman, Naomi
AU  - Clancy, Jeffrey
AU  - Pickett, Brett E.
TI  - Transcriptomic meta-analysis of non-Hodgkin’s B-cell lymphomas reveals reliance on pathways associated with the extracellular matrix
AID  - 10.1101/2022.04.28.22274444
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2022.04.28.22274444
4099  - http://medrxiv.org/content/early/2022/04/29/2022.04.28.22274444.short
4100  - http://medrxiv.org/content/early/2022/04/29/2022.04.28.22274444.full
AB  - Approximately 450,000 cases of Non-Hodgkin’s lymphoma are diagnosed annually worldwide, resulting in ∼240,000 deaths. An augmented understanding of the common mechanisms of pathology among relatively large numbers of B-cell Non-Hodgkin’s Lymphoma (BCNHL) patients is sorely needed. We consequently performed a large transcriptomic meta-analysis of available BCNHL RNA-sequencing data from GEO, consisting of 322 relevant samples across ten distinct public studies, to find common underlying mechanisms across BCNHL subtypes. The study was limited to GEO’s publicly available human B-cell RNA-sequencing datasets that met our criteria, and limitations may include lack of diversity in ethnicities and age groups. We found ∼10,400 significant differentially expressed genes (FDR-adjusted p-value < 0.05) and 33 significantly modulated pathways (Bonferroni-adjusted p-value < 0.05) when comparing lymphoma samples to non-diseased samples. Our findings include a significant class of proteoglycans not previously associated with lymphomas as well as significant modulation of extracellular matrix-associated proteins. Our drug prediction results yielded new candidates including ocriplasmin and collagenase. We also used a machine learning approach to identify the BCNHL biomarkers YES1, FERMT2, and FAM98B, novel biomarkers of high predictive fidelity. This meta-analysis validates existing knowledge while providing novel insights into the inner workings and mechanisms of B-cell lymphomas that could give rise to improved diagnostics and/or therapeutics. No external funding was used for this study.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study ONLY used publicly available human data that were originally located at the Gene Expression Omnibus database, hosted by NCBI (https://www.ncbi.nlm.nih.gov/geo/).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe study ONLY used publicly available human data that were originally located at the Gene Expression Omnibus database, hosted by NCBI (https://www.ncbi.nlm.nih.gov/geo/). https://www.ncbi.nlm.nih.gov/geo/